SPI Premium Insight: Optum’s Date With Destiny as EMIS Acquisition Decision Looms

Written by Mark Lazell

Published: March 23, 2023

By tomorrow, Optum Health must respond to the UK’s Competition and Markets Authority (CMA) objections over its planned acquisition of EMIS. If approved, the £1.24B ($1.52B) deal for the UK’s leading primary care EHR vendor promises to have wide-reaching implications for the NHS.  

The Signify View 

The CMA’s principal objections to the acquisition, announced last June, revolve around its potential impact on the competitive landscape of the UK’s drug Clinical Decision Support (CDS) and population health management (PHM) markets. 

Already have an account? Sign in here

Related Report

EMR/EHR Market Intelligence Service

Ongoing series of reports delivered over the year

EMR/EHR Market Intelligence Service

This Market Intelligence Service provides regular data, insights and analysis on the global market opportunity for Electronic Medical Records.

Find out more